投资者

/投资者
投资者 2018-05-30T18:41:16+00:00

Oramed Pharmaceuticals Inc.
(ORMP) – NasdaqCM

3.25
0.01 (0.31%)
Refresh Quote
Exchange :NASDAQ (US Dollar)
Ric Code :ORMP
Volume :20,944
Date :02-15-2019

* Minimum 20 minute delay See terms

Oramed Pharmaceuticals (NASDAQ: ORMP) has developed innovative technology to transform injectable treatments into oral therapies.

Oramed’s flagship product, an oral insulin capsule, can better the lives of millions of diabetics around the world – allowing, amongst other things, type 2 patients to begin insulin therapy earlier without fear of needles… [READ MORE >]

Oramed to Present at BIO CEO & Investor Conference

二月 6th, 2019|Oramed to Present at BIO CEO & Investor Conference已关闭评论

NEW YORK, Feb. 6, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate [...]

Oramed Initiates Phase I Oral GLP-1 Study Under IND

一月 22nd, 2019|Oramed Initiates Phase I Oral GLP-1 Study Under IND已关闭评论

JERUSALEM, Jan. 22, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has begun recruitment for its [...]

Oramed Pharmaceuticals’ CEO Letter to Shareholders

一月 15th, 2019|Oramed Pharmaceuticals’ CEO Letter to Shareholders已关闭评论

JERUSALEM, Jan. 15, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com) Dear Shareholders, We opened the year 2019 with the announcement of our receipt of a $3 million milestone payment from our [...]

Oramed Receives Additional $3 Million Milestone Payment from HTIT

一月 9th, 2019|Oramed Receives Additional $3 Million Milestone Payment from HTIT已关闭评论

Totaling $33 M in payments from HTIT received to date JERUSALEM, Jan. 9, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, [...]